After a median follow-up of 13.3 months (95% CI, 9.04-18.69), the median duration of response was 18.1 months, progression ...

As employers grapple with the soaring demand for glucagon-like peptide-1 (GLP-1) medications, Eric Levin, CEO and cofounder ...

Richter transformation develops in 2%–10% of CLL cases, often with rapid clinical decline, limited chemotherapy efficacy, and ...

Elona Toska, MSc, DPhil, explores drivers of HIV in pregnant women and young mothers: biology, relationships, and postpartum ...

Rural cardiovascular disparities and limited specialist access are motivating AI decision-support adoption to help determine ...

Noel T. Brewer, PhD, former ACIP member, warns that the CDC's reduction from 17 to 11 recommended immunizations lacks ...

Patients taking ACE inhibitors and ARBs saw a 16% reduction in their risk of cancer progression (HR, 0.84; 95% CI, 0.71-0.99; ...

In this episode, Overcoming Access Barriers and Step-Edit Challenges in IgA Nephropathy Care, the panelists explore the ...

ACOs entering MSSP with higher spending were consistently more likely to earn bonuses—a gap that persisted after a 2017 ...

Among patients with steatotic liver disease (SLD), patients with alcohol-associated liver disease (ALD) carry the highest risk of cirrhosis, followed by those with metabolic dysfunction–associated ...

Personal factors explained significant variance in five of six participation outcomes (R² 13%–48%), while environmental factors added ~11% for satisfaction and ~11% for GPS-based activity. Perceived ...

An investigational oral glucagon-like peptide-1 (GLP-1) receptor agonist, orforglipron (Eli Lilly), demonstrated superior ...